Akorn, Cipla sign agreement over unnamed inhalation drug Fred's reviews its options after releasing Q3 results TPG Capital to acquire Axcan Pharma for $1.3 billion CVS posts November financial results FTC accepts A&P's proposed Pathmark acquisition Isis grants Excaliard license for development of antisense drugs Campbell Reports First Quarter Results. Target sees disappointing Q3 sales Pfizer adds to its portfolio with Coley acquisition J&J combats slow sales with creation of three units First Previous 342 343 344 345 346 Next Last
